{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:19:43Z","timestamp":1791314383055,"version":"4.3.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.expneurol.2016.05.005","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T23:29:43Z","timestamp":1462663783000},"page":"99-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease"],"prefix":"10.1016","volume":"282","author":[{"given":"Vahri","family":"Beaumont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Mrzljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Dijkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Freije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Heins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rassoulpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Tombaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amyaouch","family":"Bradaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Gleyzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taneli","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Puoliv\u00e4li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kontkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn M.","family":"Javier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Neagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Deisemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ebneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Khetarpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Toledo-Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry C.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Munoz-Sanjuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2016.05.005_bb0005","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.bcp.2012.12.014","article-title":"Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges","volume":"85","author":"Albuquerque","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12039","article-title":"Structural basis of kynurenine 3-monooxygenase inhibition","volume":"496","author":"Amaral","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1471-4159.2009.05893.x","article-title":"On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo","volume":"109","author":"Amori","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0020","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1152\/jn.00791.2004","article-title":"Striatal potassium channel dysfunction in Huntington's disease transgenic mice","volume":"93","author":"Ariano","year":"2005","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0025","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bcp.2012.07.030","article-title":"Kynurenic acid inhibits glutamatergic transmission to CA1 pyramidal neurons via alpha7 nAChR-dependent and -independent mechanisms","volume":"84","author":"Banerjee","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0030","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","article-title":"Chronic quinolinic acid lesions in rats closely resemble Huntington's disease","volume":"11","author":"Beal","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0035","article-title":"The PDE1\/5 inhibitor SCH-51866 does not modify disease progression in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Beaumont","year":"2014","journal-title":"PLoS currents"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0040","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1124\/dmd.112.046532","article-title":"Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048","volume":"40","author":"Beconi","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0045","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/ejn.12160","article-title":"Kynurenic acid, by targeting alpha7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo","volume":"37","author":"Beggiato","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnins.2014.00012","article-title":"Kynurenines in CNS disease: Regulation by inflammatory cytokines","volume":"8","author":"Campbell","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","article-title":"The kynurenine pathway modulates neurodegeneration in a drosophila model of Huntington's disease","volume":"21","author":"Campesan","year":"2011","journal-title":"Curr. Biol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1523\/JNEUROSCI.23-03-00961.2003","article-title":"Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease","volume":"23","author":"Cepeda","year":"2003","journal-title":"J. Neurosci."},{"issue":"17","key":"10.1016\/j.expneurol.2016.05.005_bb9000","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1523\/JNEUROSCI.2137-12.2013","article-title":"Multiple sources of striatal inhibition are differentially affected in huntington's disease mouse models.","volume":"33","author":"Cepeda","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2007.12.004","article-title":"Translocator protein 18kDa (TSPO): molecular sensor of brain injury and repair","volume":"118","author":"Chen","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0070","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(88)90918-X","article-title":"Increased kynurenic acid levels in Huntington's disease","volume":"2","author":"Connick","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0070-2153(06)75002-5","article-title":"Selective neuronal degeneration in Huntington's disease","volume":"75","author":"Cowan","year":"2006","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","article-title":"The choreography of neuroinflammation in Huntington's disease","volume":"36","author":"Crotti","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041108","article-title":"Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons","volume":"7","author":"Dobelis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1006\/exnr.1993.1006","article-title":"Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization","volume":"119","author":"Ferrante","year":"1993","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","article-title":"Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease","volume":"112","author":"Forrest","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0026-895X(25)09160-6","article-title":"Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-d-aspartate receptor from rat brain","volume":"41","author":"Foster","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0105","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0110","doi-asserted-by":"crossref","first-page":"36554","DOI":"10.1074\/jbc.M113.503813","article-title":"Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain","volume":"288","author":"Giorgini","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0115","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.5473-08.2009","article-title":"Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease","volume":"29","author":"Graham","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(00)00956-3","article-title":"Early kynurenergic impairment in Huntington's disease and in a transgenic animal model","volume":"283","author":"Guidetti","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","article-title":"Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice","volume":"23","author":"Guidetti","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0135","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.1073\/pnas.96.15.8727","article-title":"Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity","volume":"96","author":"Hansson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0140","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1046\/j.0953-816x.2001.01767.x","article-title":"Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene","volume":"14","author":"Hansson","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050717","article-title":"Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease","volume":"7","author":"Heikkinen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1471-4159.1997.68010280.x","article-title":"Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues","volume":"68","author":"Heyes","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0155","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/brain\/124.5.1033","article-title":"Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection","volume":"124","author":"Heyes","year":"2001","journal-title":"Brain"},{"issue":"Pt 2","key":"10.1016\/j.expneurol.2016.05.005_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj3260351","article-title":"Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types","volume":"326","author":"Heyes","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0165","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0028-3908(93)90171-X","article-title":"Intravenous administration of l-kynurenine to rhesus monkeys: Effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid","volume":"32","author":"Jauch","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0175","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nn.3540","article-title":"Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid","volume":"16","author":"Justinova","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0180","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1742-4658.2012.08500.x","article-title":"The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders","volume":"279","author":"Kandanearatchi","year":"2012","journal-title":"FEBS J"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0185","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1471-4159.1989.tb01881.x","article-title":"A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists","volume":"52","author":"Kessler","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1471-4159.2002.00955.x","article-title":"Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain","volume":"82","author":"Kita","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0195","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.neuroscience.2010.05.052","article-title":"Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry","volume":"169","author":"Konradsson-Geuken","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0200","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1523\/JNEUROSCI.1107-14.2014","article-title":"Reduction of brain kynurenic acid improves cognitive function","volume":"34","author":"Kozak","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","article-title":"The kynurenine pathway and neurodegenerative disease","volume":"40","author":"Maddison","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0215","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jnc.12350","article-title":"Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease","volume":"127","author":"Mazarei","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001717","article-title":"HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration","volume":"11","author":"Mielcarek","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0230","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2009.06.003","article-title":"Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels","volume":"57","author":"Mok","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(91)90134-C","article-title":"Quinolinate differentiates between forebrain and cerebellar NMDA receptors","volume":"194","author":"Monaghan","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0240","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1471-4159.1988.tb04852.x","article-title":"Presence of kynurenic acid in the mammalian brain","volume":"51","author":"Moroni","year":"1988","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0245","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neuropharm.2004.10.019","article-title":"Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus","volume":"48","author":"Moroni","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0250","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1523\/JNEUROSCI.20-13-05115.2000","article-title":"Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation","volume":"20","author":"Murphy","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0255","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0022-3565(24)37160-5","article-title":"Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization","volume":"283","author":"Parsons","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","article-title":"Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease","volume":"144","author":"Pearson","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0265","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/jm00031a015","article-title":"Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase","volume":"37","author":"Pellicciari","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0270","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/exnr.2002.7885","article-title":"Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease","volume":"175","author":"Petersen","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0275","first-page":"239","article-title":"Kynurenines in cognitive functions: their possible role in depression","volume":"14","author":"Plangar","year":"2012","journal-title":"Neuropsychopharmacol Hung"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0280","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0026-895X(25)10541-5","article-title":"Pharmacological properties of recombinant human N-methyl-d-aspartate receptors comprising NR1a\/NR2A and NR1a\/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells","volume":"48","author":"Priestley","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0285","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0290","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/jm970467t","article-title":"Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase","volume":"40","author":"Rover","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0295","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","article-title":"Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington's disease","volume":"113","author":"Sathyasaikumar","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","article-title":"Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease","volume":"90","author":"Schwarcz","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0305","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bph.12230","article-title":"The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders","volume":"169","author":"Stone","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0310","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0315","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","article-title":"Imaging microglial activation in Huntington's disease","volume":"72","author":"Tai","year":"2007","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0320","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0325","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1021\/jm501350y","article-title":"Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease","volume":"58","author":"Toledo-Sherman","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0330","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nn.3691","article-title":"Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice","volume":"17","author":"Tong","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0335","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0006-8993(88)90815-3","article-title":"Identification and quantification of kynurenic acid in human brain tissue","volume":"454","author":"Turski","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0340","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/brain\/awh130","article-title":"CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy","volume":"127","author":"Valle","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2016.05.005_bb0345","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2009.02.326","article-title":"The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection","volume":"283","author":"Vamos","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0350","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fnbeh.2015.00157","article-title":"Systemic l-kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl\/6 mice","volume":"9","author":"Varga","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0355","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2014_354","article-title":"The neuropathology of Huntington's disease","volume":"22","author":"Waldvogel","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0360","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm.2092","article-title":"Kynurenine is an endothelium-derived relaxing factor produced during inflammation","volume":"16","author":"Wang","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0365","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1073\/pnas.1220068110","article-title":"Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction","volume":"110","author":"Waters","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0370","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1074\/jbc.M410039200","article-title":"Ric-3 promotes functional expression of the nicotinic acetylcholine receptor alpha7 subunit in mammalian cells","volume":"280","author":"Williams","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0375","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/1087057113489731","article-title":"Development of LC\/MS\/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)","volume":"18","author":"Winkler","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0380","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12031-009-9235-2","article-title":"The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex","volume":"40","author":"Wu","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0385","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00702-010-0573-6","article-title":"Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease","volume":"118","author":"Zadori","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2016.05.005_bb0390","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616301182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616301182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T01:48:49Z","timestamp":1748915329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488616301182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":79,"alternative-id":["S0014488616301182"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.05.005","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}